SaluTech is developing a novel conductive biomaterial (CBM) which represents a game-changing technology in AF treatment. Incorporated into a biocompatible, safe, long-lasting membrane that covers the entire atria, CBM mimics the conductive velocity of the healthy heart and helps resynchronize erratic electrical signals characteristic of AF. Pre-clinical small and large animal research data supports that CBM can nearly eliminate AF occurrence and improve overall heart function.